Liver Transplantation for Malignancy
- 1 April 2005
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 10 (4), 269-281
- https://doi.org/10.1634/theoncologist.10-4-269
Abstract
Learning Objectives: After completing this course, the reader will be able to: List the indications for liver transplantation in patients with hepatobiliary malignancies.Describe the MELD and PELD system.Discuss the management and treatment algorithm of a patient with hepatobiliary malignancy. Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com Liver transplantation for hepatic malignancies has emerged from an exotic and desperate approach to a well-documented and proven treatment modality for these unfortunate patients. However, early unsatisfactory results emphasized that only a highly selected patient population would benefit from transplantation. Currently, <10% of all liver transplants performed are for hepatocellular cancer (HCC). There is no controversy that hepatoblastoma is an excellent indication in pediatric patients with unresectable tumors. Similarly, liver transplantation for HCC in the adult population yields good results for patients whose tumor masses do not exceed the Milan criteria. It remains to be determined whether patients with more extensive tumors can be reliably selected to benefit from the procedure. Adjunctive procedures like radiofrequency ablation, chemoembolization, or cryotherapy might be indicated to limit tumor progression for patients on waiting lists. Epitheloid hemangioendothelioma is also an appropriate indication for liver transplantation, unlike angiosarcoma. Metastatic liver disease is not an indication for liver transplantation, with the exception of cases in which the primary is a neuroendocrine tumor, for which liver transplantation can result in long-term survival and even cure in a number of patients. And finally, while gallbladder cancers are never an indication for liver transplantation, rare cases of cholangiocellular cancer might qualify if aggressive combination therapies, including chemotherapy and radiotherapy followed by OLT, are carried through. Survival in these selected patients can approach that for patients with cholestatic liver disease.Keywords
This publication has 55 references indexed in Scilit:
- Outcome of liver transplantation for patients infected by hepatitis C, including those infected by genotype 4Liver Transplantation, 2003
- IntroductionThe American Journal of Medicine, 1999
- Epidemiology of hepatitis C in the United StatesThe American Journal of Medicine, 1999
- Natural history of hepatitis CThe American Journal of Medicine, 1999
- Hepatitis C virus genotypes and quasispeciesThe American Journal of Medicine, 1999
- The Increasing Incidence of Hepatocellular CarcinomaThe New England Journal of Medicine, 1999
- Rising Incidence of Hepatocellular Carcinoma in the United StatesThe New England Journal of Medicine, 1999
- Hepatitis C Virus Genotypes in the United States: Epidemiology, Pathogenicity, and Response to Interferon TherapyAnnals of Internal Medicine, 1996
- Risk Factors for Hepatocellular Carcinoma among Patients with Chronic Liver DiseaseThe New England Journal of Medicine, 1993
- Hepatocellular Carcinoma in Italian Patients with CirrhosisThe New England Journal of Medicine, 1991